"A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma." by Lihua E. Budde

Selected Works of John M. Pagel, MD, PhD

Article

A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma.

Blood (2009)

Lihua E. Budde, Fred Hutchinson Cancer Research Center
Michelle M. Zhang, Fred Hutchinson Cancer Research Center
Andrei R. Shustov, Fred Hutchinson Cancer Research Center
John M. Pagel, Fred Hutchinson Cancer Research Center
Thomas A. Warr
Tara L Chen, Seattle Cancer Care Alliance
George R. Oliveira, University of Washington
Ted Gooley, Fred Hutchinson Cancer Research Center
Ajay K. Gopal, Fred Hutchinson Cancer Research Center

Link

Disciplines

Publication Date

November 20, 2009

Citation Information

Lihua E. Budde, Michelle M. Zhang, Andrei R. Shustov, John M. Pagel, et al.. "A Phase I Study of Vorinostat (V) in Combination with Rituximab (R), Ifosphamide, Carboplatin, and Etoposide (ICE) for Patients with Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma." Blood Vol. 114 Iss. 22 (2009) p. 3696 - 3696
Available at: http://works.bepress.com/john-pagel/207/